Advancements in Clinical Research and Development of Obesity Treatment Medications Long acting amylin related peptides as therapies for obesity and type 2 diabetes ScienceDirect In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Novo Nordisk's latest trial results for its next generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent form of weight loss Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect